---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-008486"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:35:43.087249+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics Q1 net loss $13.3M; cash $371.2M; DT-216 Phase 1 underway

## Summary
- Net loss of $13.3M for Q1 2022; R&D expenses $8.8M, G&A $4.6M.
- Cash, cash equivalents and marketable securities of $371.2M as of March 31, 2022.
- DT-216 Phase 1 single-ascending dose trial in Friedreich ataxia patients; topline data expected H2 2022.
- DT-216 received FDA Fast Track designation for FA.
- Preclinical data for Fuchs endothelial corneal dystrophy GeneTAC molecules showed up to 99% reduction in toxic RNA foci.

## SEC filing metadata
- accession: 0000950170-22-008486
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000095017022008486/0000950170-22-008486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000095017022008486/dsgn-20220509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-008486
- JSON: https://secwatch.observer/filing/0000950170-22-008486.json
- Plain text: https://secwatch.observer/filing/0000950170-22-008486.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.